公开(公告)号：US20180318269A1

公开(公告)日：2018-11-08

申请号：US16033008

申请日：2018-07-11

Applicant: STC.UNM

Inventor： Eric R. Prossnitz ,  Geetanjali Sharma ,  Matthias Barton ,  Matthias R. Meyer

IPC: A61K31/436 ,  A61K31/4355 ,  A61K31/16 ,  A61K31/435 ,  A61K31/437

CPC classification number: A61K31/436 ,  A61K31/16 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/7088 ,  A61K38/28 ,  G01N2800/042

Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

公开(公告)号：US10561648B2

公开(公告)日：2020-02-18

申请号：US16067721

申请日：2017-01-09

Applicant: STC.UNM

Inventor： Pamela Hall ,  Eric R. Prossnitz ,  Helen J. Hathaway

IPC: A61K31/473 ,  A61K45/06 ,  A61K35/644 ,  A61K38/14 ,  C07K14/705 ,  A61K31/4741 ,  A61P31/04

Abstract: The present invention is directed to the use of compounds which are modulators of the G protein-Coupled Estrogen Receptor (GPER) for the inhibition —and/or treatment of Bacterial infections, especially including metMctHin-resistant Staphylococcus aureus (MRSA) infections. Pharmaceutical compositions and methods of treatment of bacterial pathogens, including MRSA are also described.

公开(公告)号：US20190000830A1

公开(公告)日：2019-01-03

申请号：US16067721

申请日：2017-01-09

Applicant: STC.UNM

Inventor： Pamela Hall ,  Eric R. Prossnitz ,  Helen J. Hathaway

IPC: A61K31/473 ,  A61K45/06 ,  A61P31/04

CPC classification number: A61K31/473 ,  A61K31/4741 ,  A61K35/644 ,  A61K38/14 ,  A61K45/06 ,  A61P31/04 ,  C07K14/70567 ,  A61K2300/00

Abstract: The present invention is directed to the use of compounds which are modulators of the G protein-Coupled Estrogen Receptor (GPER) for the inhibition—and/or treatment of Bacterial infections, especially including metMctHin-resistant Staphylococcus aureus (MRSA) infections. Pharmaceutical compositions and methods of treatment of bacterial pathogens, including MRSA are also described.

公开(公告)号：US10471047B2

公开(公告)日：2019-11-12

申请号：US16033008

申请日：2018-07-11

Applicant: STC.UNM

Inventor： Eric R. Prossnitz ,  Geetanjali Sharma

IPC: A61K31/436 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/16 ,  A61K31/7088 ,  A61K38/28

Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

公开(公告)号：US20190160047A1

公开(公告)日：2019-05-30

申请号：US16262461

申请日：2019-01-30

Applicant: STC.UNM

Inventor： Eric R. Prossnitz ,  Matthias Barton ,  Matthias R. Meyer

IPC: A61K31/436 ,  A61K31/16 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/435

Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

公开(公告)号：US10682341B2

公开(公告)日：2020-06-16

申请号：US16262461

申请日：2019-01-30

Applicant: STC.UNM

Inventor： Eric R. Prossnitz ,  Matthias Barton ,  Matthias R. Meyer

IPC: A61K31/436 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/16 ,  A61K31/7088 ,  A61K38/28

Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

公开(公告)号：US10251870B2

公开(公告)日：2019-04-09

申请号：US15556055

申请日：2016-03-02

Applicant: STC.UNM

Inventor： Eric R. Prossnitz ,  Matthias Barton ,  Matthias R. Meyer

IPC: A61K31/436 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/16 ,  A61K31/7088 ,  A61K38/28

Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).